High-dose immunoglobulin-dependent chronic demyelinating inflammatory polyneuropathy successfully managed with subcutaneous immunoglobulin using pharmacokinetic analysis

Immunoglobulin G therapy for chronic inflammatory demyelinating polyneuropathy (CIDP) often requires individual dose adjustments because of the heterogeneity of pathogenesis and varying catabolic rates. However, currently available pharmacokinetic studies of immunoglobulin G therapy do not consider...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiya, Satomi, Fujiwara, Satoru, Tanaka, Fumiaki, Kohara, Nobuo, Kawamoto, Michi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121235/
https://www.ncbi.nlm.nih.gov/pubmed/35603015
http://dx.doi.org/10.1016/j.ensci.2022.100404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121235/
https://www.ncbi.nlm.nih.gov/pubmed/35603015
http://dx.doi.org/10.1016/j.ensci.2022.100404

Ejemplares similares